报价延迟最少15分钟:2025/03/28 08:23 EDT
|
|
|
|
|
||||||||||||
|
|
|
|
|
1.89 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-6.58/-5.28
|
|
企业价值
39.47M
|
| 资产负债 |
|
每股账面净值
0.47
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
0
|
|
每股收益
0.05
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
报价延迟最少15分钟：2025/03/28 08:23 EDT
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to effectively and safely restore healthy immune balance in patients with autoimmune & inflammatory diseases driven by pathological immune dysfunction. Q32 is advancing antibody-based therapeutic candidates designed to target two central pathways of adaptive & innate immunity. The adaptive immune system is largely composed of T- & B-cell mediated cellular & antibody responses, while the innate immune system is the body's first line of defense employing leukocytes that are responsible for clearing pathogens and cellular debris and modulating T- & B-cell function. ADX-097, the lead product candidate from Q32's complement inhibitor platform, is a humanized anti-C3d monoclonal antibody fusion protein. |